Logo do repositório
 
Publicação

Portuguese guide lines for the use of biological agents in rheumatoid arthritis - october 2011 update

2011-10Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorFonseca, João Eurico
dc.contributor.authorBernardes, Miguel
dc.contributor.authorCanhão, Helena
dc.contributor.authorCanhão, Helena
dc.contributor.authorSantos, Maria José
dc.contributor.authorQuintal, Alberto
dc.contributor.authorMalcata, Armando
dc.contributor.authorNeto, Adriano
dc.contributor.authorCordeiro, Ana
dc.contributor.authorRodrigues, Ana
dc.contributor.authorMaria Rodrigues, Ana
dc.contributor.authorMourão, Ana Filipa
dc.contributor.authorRibeiro, Ana Sofia
dc.contributor.authorCravo, Ana Rita
dc.contributor.authorBarcelos, Anabela
dc.contributor.authorCardoso, Anabela
dc.contributor.authorVilar, António
dc.contributor.authorBraña, Arecili
dc.contributor.authorMalcata, Armando
dc.contributor.authorFaustino, Augusto
dc.contributor.authorSilva, Candida
dc.contributor.authorDuarte, Cátia
dc.contributor.authorAraújo, Domingos
dc.contributor.authorNour, Dolores
dc.contributor.authorVieira-Sousa, Elsa
dc.contributor.authorSimões, Eugénia
dc.contributor.authorGodinho, Fátima
dc.contributor.authorBrandão, Filipe
dc.contributor.authorVentura, Francisco
dc.contributor.authorSequeira, Graça
dc.contributor.authorFigueiredo, Guilherme
dc.contributor.authorCunha, Inês
dc.contributor.authorde Matos, J. Alves
dc.contributor.authorBranco, Jaime
dc.contributor.authorBranco, Jaime
dc.contributor.authorRamos, Maria João
dc.contributor.authorCosta, José António
dc.contributor.authorGomes, José António Melo
dc.contributor.authorPinto, José
dc.contributor.authorda Silva, José Canas
dc.contributor.authorda Silva, JA Pereira
dc.contributor.authorPatto, José Vaz
dc.contributor.authorCosta, Lúcia
dc.contributor.authorMiranda, Luís Cunha
dc.contributor.authorInês, Luís Sousa
dc.contributor.authorSantos, Luís Maurício
dc.contributor.authorCruz, Margarida
dc.contributor.authorSalvador, Maria João
dc.contributor.authorFerreira, Maria Júlia
dc.contributor.authorRial, Maria
dc.contributor.authorQueiroz, Mário Viana
dc.contributor.authorBogas, Mónica
dc.contributor.authorAraújo, Paula
dc.contributor.authorReis, Paulo
dc.contributor.authorAbreu, Pedro
dc.contributor.authorMachado, Pedro
dc.contributor.authorPinto, Patrícia
dc.contributor.authorAndré, Rui
dc.contributor.authorMelo, Rui
dc.contributor.authorGarcês, Sandra
dc.contributor.authorCortes, Sara
dc.contributor.authorAlcino, Sérgio
dc.contributor.authorRamiro, Sofia
dc.contributor.authorRamiro, Sofia
dc.contributor.authorCapela, Susana
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblSociedade Portuguesa de Reumatologia
dc.date.accessioned2017-07-14T22:01:43Z
dc.date.available2017-07-14T22:01:43Z
dc.date.issued2011-10
dc.description.abstractThe authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of Rheumatoid Arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in the case of non-responders. Biological treatment (with a tumour necrosis factor antagonist, abatacept or tocilizumab) should be considered in RA patients with a disease activity score 28 (DAS 28) equal to or greater than 3.2 des pite treatment with at least 20mg-weekly-dose of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 3 months of other conventional disease modifying drug or combination therapy. A DAS 28 score between 2.6 and 3.2 with a significant functional or radiological deterioration under treatment with conventional regi -mens could also constitute an indication for biological treatment. The treatment goal should be remission or, if that is not achievable, at least a low disease activity, defined by a DAS28 lower than 3.2,without significative functional or radiological worsening. The response criteria, at the end of the first 3 months of treatment, are a decrease of at least 0.6 in the DAS28 score. After 6 months of treatment res ponse criteria is defined as a decrease greater than 1.2 in the DAS28 score. Non-responders, in accordance to the Rheumatologist's clinical opi -nion, should try a switch to another biological agent (tumour necrosis factor antagonist, abatacept, rituxi mab or tocilizumab).en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent4
dc.format.extent99846
dc.identifier.issn0303-464X
dc.identifier.otherPURE: 2303055
dc.identifier.otherPURE UUID: b4838ed2-e96c-4980-8e67-b43290ce2e06
dc.identifier.otherScopus: 84863009200
dc.identifier.otherPubMed: 22472929
dc.identifier.otherWOS: 000299798400007
dc.identifier.otherORCID: /0000-0003-1894-4870/work/67178163
dc.identifier.urihttp://www.scopus.com/inward/record.url?scp=84863009200&partnerID=8YFLogxK
dc.identifier.urlhttps://www.scopus.com/pages/publications/84863009200
dc.language.isoeng
dc.peerreviewedyes
dc.subjectBiological Thera -pies
dc.subjectGuidelines
dc.subjectRheumatoid arthritis
dc.subjectRheumatology
dc.titlePortuguese guide lines for the use of biological agents in rheumatoid arthritis - october 2011 updateen
dc.typejournal article
degois.publication.firstPage385
degois.publication.issue4
degois.publication.lastPage388
degois.publication.titleActa Reumatológica Portuguesa
degois.publication.volume36
dspace.entity.typePublication
person.familyNameCanhão
person.familyNameRodrigues
person.familyNameBranco
person.familyNameRamiro
person.givenNameHelena
person.givenNameAna Maria
person.givenNameJaime
person.givenNameSofia
person.identifier379800
person.identifier405554
person.identifier.ciencia-id5A17-C6D9-DBC8
person.identifier.ciencia-idAE18-DA10-460C
person.identifier.ciencia-idB612-E5C3-60DC
person.identifier.ciencia-idC513-D4F1-EEC3
person.identifier.orcid0000-0003-1894-4870
person.identifier.orcid0000-0003-2046-8017
person.identifier.orcid0000-0001-7024-4375
person.identifier.orcid0000-0002-8899-9087
person.identifier.ridC-9611-2018
person.identifier.scopus-author-id6602393492
person.identifier.scopus-author-id57189499663
person.identifier.scopus-author-id8417815400
rcaap.rightsopenAccess
relation.isAuthorOfPublicationc87f58c0-b53d-4321-9bd7-39554e6001b5
relation.isAuthorOfPublicatione2b860b7-6a22-4bc8-a7ff-676ca22da61c
relation.isAuthorOfPublication4caea9f3-40dd-4c95-98ec-0120509287c0
relation.isAuthorOfPublication9853406a-2641-440d-a8b1-a516bdb6f32f
relation.isAuthorOfPublication.latestForDiscoverye2b860b7-6a22-4bc8-a7ff-676ca22da61c

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
ARP_2011_5_10_PC_PTGuidelines_ARP2011_115.pdf
Tamanho:
97.51 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista nacional com arbitragem científica